Last edition
News about "ASCO 2026"
US FDA Accepts NDA for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer
The US FDA has accepted Genentech’s New Drug Application (NDA) for giredestrant, an investigational oral SERD for ER-positive early-stage breast cancer. Supported by positive phase 3 trial results, giredestrant is the first and only oral SERD to demonstrate efficacy in the curative setting.
ASCO 2026 | 03/06/2026 | By News Bureau
Medidata Launches Next-Gen AI Imaging Solution for Faster Clinical Trials
Medidata unveiled next-generation AI-powered imaging capabilities within the Medidata Data Experience at ASCO 2026, enabling faster, more precise clinical trials.
ASCO 2026 | 02/06/2026 | By News Bureau | 142
Pfizer's BRAFTOVI Nearly Doubles Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer reported phase 3 BREAKWATER trial results showing that the BRAFTOVI regimen nearly doubled median Progression-Free Survival (PFS) in patients with metastatic colorectal cancer, reducing the risk of disease progression or death by 56 percent and the risk of death by 44 percent compared with standard chemotherapy in BRAF V600E-mutant disease.
ASCO 2026 | 01/06/2026 | By News Bureau
A large-scale study involving more than 6,800 lymphoma patients found that CAR T-cell therapy delivered at non-FACT accredited centres achieved outcomes comparable to accredited facilities, supporting efforts to expand access to advanced cancer treatments closer to patients’ homes.
ASCO 2026 | 30/05/2026 | By News Bureau
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.
ASCO 2026 | 30/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy